NAD+ IV therapy: an expensive drip ahead of its evidence

NAD+ IV therapy is one of the wellness industry’s best marketing stories: a fundamental cellular molecule, declining with age, dripped straight into your veins to restore youth and energy. The molecule is real and genuinely important. The drip’s evidence is where the story falls apart — and where an honest read can save you several hundred dollars a session.

The molecule is real; the drip’s evidence isn’t

NAD+ (nicotinamide adenine dinucleotide) is an essential coenzyme in cellular energy metabolism, and its levels do fall with age — that part is solid biology. The leap is the delivery. The rigorous human evidence on raising NAD+ comes almost entirely from oral precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — not intravenous NAD+ itself. In a controlled study, oral NR roughly doubled blood NAD+ in healthy volunteers,^[2]and NR has been tested in randomized trials in conditions like Parkinson’s.^[3] For intravenous NAD+ specifically, there is no controlled trial demonstrating the anti-aging, energy, or longevity benefits the drips are sold for. See our NAD+ precursors monograph for the route that actually has the data.

The one human IV study just measured the blood

The closest thing to direct evidence is a small pharmacokinetic pilot: researchers ran a 6-hour intravenous NAD+ infusion and tracked what happened to it. The finding wasn’t a health benefit — it was that infused NAD+ is rapidly removed from the plasma (no rise in circulating NAD+ for the first two hours, with increased breakdown products excreted in urine by hour six).^[1] In other words, the only human study of an IV NAD+ infusion measured its metabolism, not any clinical outcome — and even on metabolism, it complicates the simple “flood your cells with NAD+” pitch.

The addiction-recovery claim

Some clinics market NAD+ drips heavily for addiction and withdrawal. The published human support for this is uncontrolled case series — descriptive reports without randomization or a placebo group, several from a single connected network.^[1] Uncontrolled case reports can motivate a trial; they cannot establish that an expensive infusion treats addiction. Until a controlled trial exists, this claim should be read as marketing, not medicine.

If you care about NAD+, what actually has support

None of this means NAD+ biology is bunk — it means the intravenous drip is the wrong place to spend on it. The human evidence base lives with the oral precursors: NR and NMN reliably raise blood NAD+ in controlled studies, cost a fraction of a drip, and don’t require a clinic visit.^[2][3] Whether even that translates into anti-aging outcomes is still an open question — but it’s a far more defensible place to start than an IV bag.

The honest bottom line

NAD+ IV therapy is a textbook case of a real molecule sold through an unproven delivery method at a premium price. There is no controlled trial showing intravenous NAD+ delivers its marketed anti-aging, energy or addiction benefits; the one human IV study found the infused NAD+ is cleared from the blood quickly; and it’s an unregulated, compounded, non-approved service.^[1] If NAD+ interests you, the evidence points to the oral-precursor route, not the drip — see our NAD+ precursors guide.